TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Core Viewpoint - TransCode Therapeutics, Inc. has announced a public offering of 10,250,000 shares of common stock and warrants, aiming to raise approximately $10 million for product development and working capital [1][2]. Group 1: Offering Details - The shares are priced at $0.98 each, with warrants having an exercise price of $0.86, immediately exercisable for five years [1]. - The offering is expected to close on March 25, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to product development activities, including clinical trials for TTX-MC138, the company's lead therapeutic candidate, and for general corporate purposes [2]. Group 3: Company Overview - TransCode is a clinical-stage oncology company focused on treating metastatic disease through RNA therapeutics, utilizing its proprietary TTX nanoparticle platform [6]. - The lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a biomarker associated with metastasis [6].